Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 3/Safety & Efficacy of Esomeprazole in Infants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00468559
Recruitment Status : Completed
First Posted : May 2, 2007
Results First Posted : June 2, 2014
Last Update Posted : June 2, 2014
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
The purpose of this study is to look at the improvement of a once a day dose of esomeprazole for reducing the signs and symptoms of infants with gastroesophageal reflux disease (GERD). This research study consists of a screening, open-label, and double-blind treatment withdrawal phase. The screening phase ensures the patient eligibility. No study medication is dispensed during the screening phase. During the open-label phase, patients are administered esomeprazole 2.5mg, 5.0mg or 10.0mg based on his/her weight. During the double-blind phase, the patients are administered either his/her open-label dose or placebo. Double-blind means neither the physician, parent, or patient will know if patient is taking esomeprazole or placebo. The patient will have an equal chance of receiving esomeprazole or placebo.

Condition or disease Intervention/treatment Phase
Gastroesophageal Reflux Disease (GERD) Drug: Open Label Run In Esomeprazole Drug: Double Blind Esomeprazole Drug: Double Blind Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 98 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Treatment-withdrawal Study to Evaluate the Efficacy and Safety of Esomeprazole for the Treatment of Gastroesophageal Reflux (GERD) in Infants Aged 1 to 11 Months, Inclusive
Study Start Date : April 2007
Actual Primary Completion Date : June 2008
Actual Study Completion Date : June 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: GERD

Arm Intervention/treatment
Experimental: Open Label Esomeprazole
This is an open label, run-in phase. All patients received Esomeprazole.
Drug: Open Label Run In Esomeprazole
Esomeprazole magnesium in capsules dosing weight-dependent (2.5 mg - 10 mg)

Experimental: Double Blind Esomeprazole
This is the double blind withdrawal phase. Patients are randomized to active drug or placebo.
Drug: Double Blind Esomeprazole
Esomeprazole magnesium in capsules dosing weight-dependent (2.5 mg - 10 mg)

Placebo Comparator: Double Blind Placebo
This is the double blind withdrawal phase. Patients are randomized to active drug or placebo.
Drug: Double Blind Placebo
Double Blind Placebo




Primary Outcome Measures :
  1. Number of Participants Discontinuing Due to Symptom Worsening in the Randomized Treatment Withdrawal Phase (Treatment Withdrawal Phase Endpoint) [ Time Frame: Treatment-withdrawal phase (up to 4 weeks following randomization, or until earlier discontinuation from the study) ]
    Number of participants discontinuing during the 4-week of randomized double-blind withdrawal phase that met the pre-set definition of symptom worsening criteria.


Secondary Outcome Measures :
  1. Number of Participants Discontinuing Due to Any Reason, Including Symptom Worsening, in the Randomized Treatment Withdrawal Phase (Treatment Withdrawal Phase Endpoint) [ Time Frame: Treatment withdrawal phase (up to 4 weeks following randomization, or until earlier discontinuation from the study) ]
    Number of participants discontinuing due to any reason was identical to the number of participants discontinuing due to symptom worsening (the primary assessment) when no participants discontinued due to reason other than symptom worsening.

  2. Treatment Successes at the End of the 4-week Double-blind Treatment Withdrawal Phase (Treatment Withdrawal Phase Endpoint). [ Time Frame: Treatment withdrawal phase (up to 4 weeks following randomization, or until earlier discontinuation from the study) ]

    The number of participants reaching the end of the treatment withdrawal phase without discontinuing from the study (for any reason) or showing symptom worsening in the physician global assessment of Gastroesophageal Reflux Disease (GERD) symptoms. Based on the severity of symptoms reported by the parent/guardian in IVRS, the investigator provided the overall clinical impression of the patient's GERD-related symptoms over the last 7 days as:

    None Mild Moderate Severe


  3. Physician's Global Assessment (PGA) of Gastroesophageal Reflux Disease (GERD) Symptoms (Treatment Withdrawal Phase Endpoint) [ Time Frame: Treatment withdrawal phase (up to 4 weeks following randomization, or until earlier discontinuation from the study) ]
    Percentage of participants with Physician's Global Assessment (PGA) score at the final treatment withdrawal assessment in following categories: None (no symptoms), Mild, Moderate or Severe. The worst post-randomization Physician's Global Assessment (PGA) assessment during double blind phase is taken into account.

  4. Severity of Vomiting/Regurgitation Symptoms as Reported by the Parent/Guardian (Treatment Withdrawal Phase Endpoint) [ Time Frame: Treatment withdrawal phase (up to 4 weeks following randomization, or until earlier discontinuation from the study) Change was calculated from baseline to last measure obtained ]
    Change from baseline in symptom severity (Severity is scored as 0-4 [none, mild moderate, severe]). For each participant, final severity score is the mean severity in the final 7-days, while baseline is the mean severity in the 7-day period up to and including randomization. Changes less than zero indicate improved severity versus baseline. Participants needed baseline measure and one additional post baseline measure to be included in analysis.

  5. Severity of Irritability Crying/Fussing Symptoms as Reported by the Parent/Guardian (Treatment Withdrawal Phase Endpoint) [ Time Frame: Treatment withdrawal phase (up to 4 weeks following randomization, or until earlier discontinuation from the study) Change was calculated from baseline to last measure obtained ]
    Change from baseline in symptom severity (Severity is scored as 0-4 [none, mild moderate, severe]). For each participant, final severity score is the mean severity in the final 7-days, while baseline is the mean severity in the 7-day period up to and including randomization. Changes less than zero indicate improved severity versus baseline. Participants needed baseline measure and one additional post baseline measure to be included in analysis.

  6. Severity of Supraesophageal/Respiratory Disturbances (Coughing/Wheezing,Labored Breathing) as Reported by Parent/Guardian (Treatment Withdrawal Phase Endpoint) [ Time Frame: Treatment withdrawal phase (up to 4 weeks following randomization, or until earlier discontinuation from the study) Change was calculated from baseline to last measure obtained ]
    Change from baseline in symptom severity (Severity is scored as 0-4 [none, mild moderate, severe]). For each participant, final severity score is the mean severity in the final 7-days, while baseline is the mean severity in the 7-day period up to and including randomization. Changes less than zero indicate improved severity versus baseline. Participants needed baseline measure and one additional post baseline measure to be included in analysis.

  7. Severity of Feeding Difficulties Reported by Parent/Guardian (Treatment Withdrawal Phase Endpoint) [ Time Frame: Treatment withdrawal phase (up to 4 weeks following randomization, or until earlier discontinuation from the study) Change was calculated from baseline to last measure obtained ]
    Change from baseline in symptom severity (Severity is scored as 0-4 [none, mild moderate, severe]). For each participant, final severity score is the mean severity in the final 7-days, while baseline is the mean severity in the 7-day period up to and including randomization. Changes less than zero indicate improved severity versus baseline. Participants needed baseline measure and one additional post baseline measure to be included in analysis.

  8. Improvement in Physician's Global Assessment (PGA) Following Open-label Esomeprazole (Open-label Phase Endpoint) [ Time Frame: Open-label treatment period (2 weeks) ]
    Number of patients who had an improvement of at least one category in the PGA at the end of open-label treatment with esomeprazole compared to baseline. Improvement in PGA was a pre-requisite for randomization into the randomized treatment withdrawal phase. Only patients with PGA at baseline and end of open-label are analyzed here.

  9. Severity of Vomiting/Regurgitation Symptoms as Reported by the Parent/Guardian (Open-label Phase) [ Time Frame: Open Label phase (Screening plus two weeks) ]
    Symptom severity (Severity is scored as 0-4 [none, mild moderate, severe]). For each participant, The score is the mean severity in each 7-day period.

  10. Severity of Irritability Crying/Fussing Symptoms as Reported by the Parent/Guardian (Open-label Phase Endpoint) [ Time Frame: Open Label Phase (Screening plus two weeks) ]
    Symptom severity (Severity is scored as 0-4 [none, mild moderate, severe]). For each participant, The score is the mean severity in each 7-day period.

  11. Severity of Supraesophageal/Respiratory Disturbances (Coughing/Wheezing,Labored Breathing) as Reported by Parent/Guardian (Open-label Phase Endpoint) [ Time Frame: Open Label Phase (Screening plus two weeks) ]
    Symptom severity (Severity is scored as 0-4 [none, mild moderate, severe]). For each participant, The score is the mean severity in each 7-day period.

  12. Severity of Feeding Difficulties as Reported by Parent/Guardian (Open-label Phase Endpoint) [ Time Frame: Open Label Phase (Screening plus two weeks) ]
    Symptom severity (Severity is scored as 0-4 [none, mild moderate, severe]). For each participant, The score is the mean severity in each 7-day period.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Month to 11 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patients' parents must sign the informed consent prior to the beginning of any study-related procedures (according to local regulations)
  • patients must have symptoms at study entry and have a clinical diagnosis of suspected GERD, symptomatic GERD, or GERD proven by a test called an endoscopy, a test using a long tube inserted in the body for diagnostic exams

Exclusion Criteria:

  • patients who have used a PPI (proton pump inhibitors; used to reduce the amount of acid in the stomach) within 7 days before enrollment in the open label treatment phase (Day 0)
  • patients with a history of acute life-threatening event

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00468559


Locations
Layout table for location information
United States, Arizona
Research Site
Phoenix, Arizona, United States
United States, Georgia
Research Site
Atlanta, Georgia, United States
United States, Illinois
Research Site
Park Ridge, Illinois, United States
United States, Kentucky
Research Site
Louisville, Kentucky, United States
United States, Louisiana
Research Site
Marrero, Louisiana, United States
United States, Massachusetts
Research Site
Newton, Massachusetts, United States
United States, Michigan
Research Site
Southfield, Michigan, United States
United States, Nevada
Research Site
Las Vegas, Nevada, United States
United States, New York
Research Site
Brooklyn, New York, United States
Research Site
New York, New York, United States
United States, Ohio
Research Site
Akron, Ohio, United States
Research Site
Dayton, Ohio, United States
United States, Tennessee
Research Site
Chattanooga, Tennessee, United States
United States, Virginia
Research Site
Roanoke, Virginia, United States
France
Research Site
Lille Cedex, France
Research Site
Paris, France
Germany
Research Site
Bochum, Germany
Research Site
Greifswald, Germany
Research Site
Nurberg, Germany
Research Site
Potsdam, Germany
Research Site
Wuppertal, Germany
Poland
Research Site
Bialystok, Poland
Research Site
Krakow, Poland
Research Site
Warszawa, Poland
Research Site
Wroclaw, Poland
Sponsors and Collaborators
AstraZeneca
Investigators
Layout table for investigator information
Study Director: Marta Ilueca AstraZeneca
Study Director: Jennifer Heckman AstraZeneca
Study Director: Jill McGuinn AstraZeneca
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00468559    
Other Study ID Numbers: D9614C00096
First Posted: May 2, 2007    Key Record Dates
Results First Posted: June 2, 2014
Last Update Posted: June 2, 2014
Last Verified: April 2014
Keywords provided by AstraZeneca:
pediatrics
neonates
Additional relevant MeSH terms:
Layout table for MeSH terms
Gastroesophageal Reflux
Esophageal Motility Disorders
Deglutition Disorders
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Esomeprazole
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action